ATE225770T1 - Difluoroprostaglandin-derivate und ihre anwendung - Google Patents

Difluoroprostaglandin-derivate und ihre anwendung

Info

Publication number: ATE225770T1
Authority: AT; Austria
Prior art keywords: group; medicine; difluoroprostaglandin; derivatives; difluoroprostaglandin derivatives
Prior art date: 1996-12-26

Application number

AT97122702T

Other languages

English (en)

Inventor

Eiichi Shirasawa

Masaaki Kageyama

Tadashi Nakajima

Takashi Nakano

Nobuaki Mori

Hideshi Sasakura

Yasushi Matsumura

Yoshitomi Morizawa

Original Assignee

Asahi Glass Co Ltd

Santen Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-26

Filing date

1997-12-22

Publication date

2002-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27301396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE225770(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-12-22 Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd

2002-10-15 Application granted granted Critical

2002-10-15 Publication of ATE225770T1 publication Critical patent/ATE225770T1/de

Links

239000003814 drug Substances 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 abstract 1
208000030533 eye disease Diseases 0.000 abstract 1
229910052731 fluorine Inorganic materials 0.000 abstract 1
239000011737 fluorine Substances 0.000 abstract 1
230000003449 preventive effect Effects 0.000 abstract 1
150000003180 prostaglandins Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT97122702T 1996-12-26 1997-12-22 Difluoroprostaglandin-derivate und ihre anwendung ATE225770T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP34861496		1996-12-26
JP7405497		1997-03-26
JP17247797		1997-06-27

Publications (1)

Publication Number	Publication Date
ATE225770T1 true ATE225770T1 (de)	2002-10-15

Family

ID=27301396

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97122702T ATE225770T1 (de)	1996-12-26	1997-12-22	Difluoroprostaglandin-derivate und ihre anwendung

Country Status (16)

Country	Link
US (2)	US5886035A (de)
EP (1)	EP0850926B1 (de)
JP (2)	JP3480549B2 (de)
KR (1)	KR100526282B1 (de)
CN (1)	CN1108289C (de)
AT (1)	ATE225770T1 (de)
CA (1)	CA2225761C (de)
DE (2)	DE122008000050I2 (de)
DK (1)	DK0850926T3 (de)
ES (1)	ES2187719T3 (de)
FR (1)	FR11C0020I2 (de)
LU (1)	LU91943I2 (de)
NL (1)	NL300407I2 (de)
NO (2)	NO317060B1 (de)
PT (1)	PT850926E (de)
TW (1)	TW536534B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0930296B2 (de) *	1996-09-17	2005-11-02	Asahi Glass Company Ltd.	Fluorierte prostaglandinderivate und medikamente
US6225348B1 (en)	1998-08-20	2001-05-01	Alfred W. Paulsen	Method of treating macular degeneration with a prostaglandin derivative
IL143477A (en)	2001-05-31	2009-07-20	Finetech Pharmaceutical Ltd	Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
IL134241A (en)	2000-01-27	2006-06-11	Finetech Pharmaceutical Ltd	Process for the preparation of latanoprost
AU2001228836A1 (en) *	2000-01-28	2001-08-07	Santen Pharmaceutical Co., Ltd.	Novel difluoroprostaglandin derivative
PT1321144E (pt) *	2000-09-13	2011-03-10	Santen Pharmaceutical Co Ltd	Colírio
EP1532981B1 (de) *	2002-08-23	2007-09-26	Santen Pharmaceutical Co., Ltd.	Stabile augentropfen enthaltend latanoprost als wirkstoff
CA2498233C (en) *	2002-09-09	2012-08-14	Santen Pharmaceutical Co., Ltd.	Clear ophthalmic solution comprising latanoprost as active ingredient
US20060199863A1 (en) *	2003-07-31	2006-09-07	Santen Pharmaceutical Co., Ltd.	Product containing prostaglandin
CN102497368A (zh) *	2003-12-08	2012-06-13	高通股份有限公司	具有改进链路同步的高数据速率接口
CA2590277C (en) *	2004-12-09	2014-07-08	Santen Pharmaceutical Co., Ltd.	Product containing prostaglandin having fluorine atom in its molecule
JP4753178B2 (ja) *	2004-12-24	2011-08-24	参天製薬株式会社	プロスタグランジンＦ２α誘導体含有製品
JP5100025B2 (ja) *	2005-03-31	2012-12-19	旭硝子株式会社	プロスタグランジンＦ２α誘導体を有効成分として含む網膜神経細胞保護剤
CN102293774A (zh) *	2005-03-31	2011-12-28	旭硝子株式会社	前列腺素F2α衍生物的应用
EP1870099A4 (de)	2005-04-13	2008-07-16	Ube Industries	Schutzmittel für retinale nervenzellen mit einem indazol-derivat als wirkstoff
JP2009500315A (ja) *	2005-06-29	2009-01-08	ファイザー・インク	フルオロプロスタグランジンのニトロ誘導体
CA2637797C (en) *	2006-02-07	2015-03-17	R-Tech Ueno, Ltd.	Method for preparing prostaglandin derivative
WO2007111806A2 (en) *	2006-03-23	2007-10-04	Massachusetts Eye And Ear Infirmary	Cyclopentane heptanoic acid compounds for reducing body fat
FR2918891B1 (fr) *	2007-07-20	2009-09-25	Thea Sa Lab	Solution ophtalmique a base de prostaglandines sans conservateur
EP2127638A1 (de)	2008-05-30	2009-12-02	Santen Pharmaceutical Co., Ltd	Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
WO2010027040A1 (ja) *	2008-09-04	2010-03-11	参天製薬株式会社	１５，１５－ジフルオロプロスタグランジンＦ2α誘導体を有効成分として含有する毛髪成長促進剤
US20110293549A1 (en)	2009-02-03	2011-12-01	Athena Cosmetics, Inc.	Composition, method and kit for enhancing hair
BR112013002584A2 (pt)	2010-08-02	2016-06-07	Pharma Patent Holding Inc	composição, processo de kit para aperfeiçoamento de cabelo
CA2824317C (en)	2011-01-19	2014-12-16	Terakine Therapeutics, Inc.	Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
TW201906614A (zh)	2011-02-04	2019-02-16	日商興和股份有限公司	青光眼或高眼壓症之預防或治療用之點眼藥
US8426471B1 (en)	2011-12-19	2013-04-23	Topokine Therapeutics, Inc.	Methods and compositions for reducing body fat and adipocytes
US20150011755A1 (en) *	2012-02-07	2015-01-08	Dr. Reddys Laboratories Limited	Amine salts of prostaglandin analogs
WO2013180229A1 (ja)	2012-05-30	2013-12-05	旭硝子株式会社	育毛用組成物
SG11201600237YA (en)	2012-11-21	2016-02-26	Topokine Therapeutics Inc	Methods and compositions for locally increasing body fat
NO2753788T3 (de)	2013-05-10	2018-06-16
US9820993B2 (en)	2013-05-15	2017-11-21	Topokine Therapeutics, Inc.	Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
CN103570549B (zh) *	2013-10-11	2016-01-27	天泽恩源（天津）制药有限公司	一种合成他氟前列素的方法
CN103804195B (zh) *	2014-01-26	2016-06-15	天泽恩源（天津）制药有限公司	一种合成他氟前列素的方法
CN103819436A (zh) *	2014-02-21	2014-05-28	天泽恩源（天津）医药技术有限公司	(3aR,4R,5R,6aS)-4-((E)-3,3-二氟-4-苯氧基丁-1-烯-1-基)-2-氧代六氢-2H-环戊烷[b]呋喃-5-基苯甲酸酯的一种晶型及相应晶体的制备方法
WO2015200425A1 (en)	2014-06-27	2015-12-30	Topokine Therapeutics, Inc.	Topical dosage regimen
KR20160116402A (ko)	2015-03-30	2016-10-10	연성정밀화학(주)	타플루프로스트의 제조방법
KR20180058758A (ko)	2015-09-22	2018-06-01	그레이버그 비젼, 인크.	안구 장애의 치료를 위한 화합물 및 조성물
CN107226790A (zh) *	2016-03-25	2017-10-03	苏州朗科生物技术有限公司	一种高纯度他氟前列素及其类似化合物的制备方法及中间体化合物
GR1009040B (el)	2016-04-19	2017-05-19	Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων	Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en)	2016-08-15	2018-02-22	Santen Pharmaceutical Co., Ltd.	Ophthalmic composition and a method for treating ocular hypertension and glaucoma
CN108299192A (zh) *	2017-01-10	2018-07-20	江苏恒瑞医药股份有限公司	一种他氟前列素酸的金属盐化合物结晶形式及其制备方法
CN106986766B (zh) *	2017-05-08	2021-01-12	扬子江药业集团有限公司	他氟前列素的制备方法
CN112457277B (zh) *	2020-12-16	2022-06-28	西安国康瑞金制药有限公司	一种他氟前列腺素的制备方法
CN112832150B (zh) *	2021-01-27	2022-06-24	中交第三公路工程局有限公司	一种涵洞通道等立面垂直凿毛装置
CN112851510B (zh) *	2021-01-27	2022-07-19	Ａｇｃ株式会社	他氟前列素的纯化方法
CN116120268A (zh) *	2023-03-06	2023-05-16	南京华威医药科技集团有限公司	一种他氟前列素中间体杂质及其制备方法
CN116425707A (zh) *	2023-03-31	2023-07-14	南京华威医药科技集团有限公司	一种他氟前列素中间体异构体杂质及其制备方法
CN117024324A (zh) *	2023-08-03	2023-11-10	南京华威医药科技集团有限公司	一种他氟前列素对映异构体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5166178B1 (en) *	1987-09-18	1998-07-21	R Tech Ueno Ltd	Ocular hypotensive agents
US5510383A (en) *	1993-08-03	1996-04-23	Alcon Laboratories, Inc.	Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH0770054A (ja) *	1993-08-30	1995-03-14	R Tec Ueno:Kk	生化学的拮抗および疾患処置剤
EP0930296B2 (de) *	1996-09-17	2005-11-02	Asahi Glass Company Ltd.	Fluorierte prostaglandinderivate und medikamente
CA2269855A1 (en) *	1996-11-12	1998-05-22	Alcon Laboratories, Inc.	15-fluoro prostaglandins as ocular hypotensives

1997
- 1997-12-12 JP JP34334397A patent/JP3480549B2/ja not_active Expired - Lifetime
- 1997-12-17 TW TW086119094A patent/TW536534B/zh not_active IP Right Cessation
- 1997-12-18 US US08/993,017 patent/US5886035A/en not_active Expired - Lifetime
- 1997-12-22 DE DE122008000050C patent/DE122008000050I2/de active Active
- 1997-12-22 ES ES97122702T patent/ES2187719T3/es not_active Expired - Lifetime
- 1997-12-22 AT AT97122702T patent/ATE225770T1/de active
- 1997-12-22 DE DE69716226T patent/DE69716226T2/de not_active Expired - Lifetime
- 1997-12-22 PT PT97122702T patent/PT850926E/pt unknown
- 1997-12-22 EP EP97122702A patent/EP0850926B1/de not_active Expired - Lifetime
- 1997-12-22 DK DK97122702T patent/DK0850926T3/da active
- 1997-12-23 NO NO19976085A patent/NO317060B1/no not_active IP Right Cessation
- 1997-12-23 CA CA002225761A patent/CA2225761C/en not_active Expired - Lifetime
- 1997-12-26 CN CN97126331A patent/CN1108289C/zh not_active Expired - Lifetime
- 1997-12-26 KR KR1019970074620A patent/KR100526282B1/ko not_active Expired - Lifetime
1998
- 1998-08-03 US US09/127,804 patent/US5985920A/en not_active Expired - Lifetime
2003
- 2003-07-31 JP JP2003284134A patent/JP3994074B2/ja not_active Expired - Lifetime
2009
- 2009-03-06 NO NO2009006C patent/NO2009006I2/no not_active IP Right Cessation
- 2009-09-02 NL NL300407C patent/NL300407I2/nl unknown
2011
- 2011-06-21 FR FR11C0020C patent/FR11C0020I2/fr active Active
2012
- 2012-02-15 LU LU91943C patent/LU91943I2/fr unknown

Also Published As

Publication number	Publication date
LU91943I2 (fr)	2012-04-16
FR11C0020I1 (de)	2011-07-29
PT850926E (pt)	2003-02-28
ES2187719T3 (es)	2003-06-16
TW536534B (en)	2003-06-11
NL300407I2 (nl)	2010-03-01
NO976085D0 (no)	1997-12-23
NO2009006I1 (no)	2009-03-16
FR11C0020I2 (fr)	2012-03-16
JP3480549B2 (ja)	2003-12-22
US5985920A (en)	1999-11-16
DE122008000050I2 (de)	2011-06-16
EP0850926A2 (de)	1998-07-01
DE69716226D1 (de)	2002-11-14
NO976085L (no)	1998-06-29
NL300407I1 (nl)	2009-11-02
EP0850926B1 (de)	2002-10-09
KR100526282B1 (ko)	2006-05-17
JP3994074B2 (ja)	2007-10-17
NO317060B1 (no)	2004-08-02
CN1187486A (zh)	1998-07-15
CA2225761C (en)	2009-04-21
DE122008000050I1 (de)	2009-01-29
NO2009006I2 (no)	2012-03-05
CN1108289C (zh)	2003-05-14
US5886035A (en)	1999-03-23
DE69716226T2 (de)	2003-06-05
EP0850926A3 (de)	1999-06-16
JP2004002462A (ja)	2004-01-08
CA2225761A1 (en)	1998-06-26
KR19980064718A (ko)	1998-10-07
DK0850926T3 (da)	2003-02-17
JPH1171344A (ja)	1999-03-16

Publication	Publication Date	Title
DE69716226D1 (de)	2002-11-14	Difluoroprostaglandin-Derivate und ihre Anwendung
DE69418243D1 (de)	1999-06-10	N-Heteroaryl-N'-Phenylharnstoffderivate, ihre Herstellung und Verwendung
KR970069985A (ko)	1997-11-07	1,2-디페닐피롤 유도체,그의 제법 및 그의 치료학적 용도
PT918776E (pt)	2004-07-30	Sintese total de acilfulvenos antitumorais
DE69222459D1 (de)	1997-11-06	Thiazolidindionderivate, ihre Herstellung und Anwendung
DK0882728T3 (da)	2003-01-06	1-methylcarbapenemderivater
ES2055235T3 (es)	1994-08-16	Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
EP1034783A4 (de)	2001-03-28	Amidederivaten
FI956151A0 (fi)	1995-12-20	Iskeemisissä taudeissa käyttökelpoisia bentseenijohdannaisia
DE69001004D1 (de)	1993-04-08	Zusammensetzung gegen leberkrankheiten.
DE69123757D1 (de)	1997-01-30	Epoxysuccinamidsäurederivat
DE69202594D1 (de)	1995-06-29	Zusammensetzung gegen Katarakt.
ATE71364T1 (de)	1992-01-15	Fluor enthaltende vitamin-d2-derivate.
DE3782229D1 (de)	1992-11-19	Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
ES2077697T3 (es)	1995-12-01	Derivados de 1-fenoxicarbonil-2-pirrolidinona y agentes nootropicos.
ES2115303T3 (es)	1998-06-16	Uso de compuestos de 5-tia-1,4-diazabiciclo(4.2.0)octan-3,8-dioxo en terapia antitumoral.